Abstract
In the bench to bedside development of drugs to treat patients with cancer, the common guide to dose and schedule selection is toxicity to normal organs patterned after the preclinical profile of the drug. An understanding of the cellular pharmacology of the drug and specifically the cellular targets linked to the drug's effect is of substantial value in assisting the clinical investigator in selecting the proper dose and schedule of drug administration. The clinical development of ara-C for the treatment of acute myeloid leukemia (AML) provides a useful paradigm for the study of this process. An understanding of the cellular pharmacology, cytokinetics and pharmacokinetics of ara-C in leukemic mice showed substantial schedule-dependency. Exposure to high doses for a short duration (C x t) resulted in a palliative therapeutic outcome. In marked contrast, exposure to lower doses for a protracted period (c x T) was curative. Clinical use of ara-C in patients with AML patterned after the murine experience, c x T approach, has been of limited benefit in terms of long-term disease-free survival. Studies with human leukemia blasts from patients have shown that for the majority of patients, the initial rate-limiting step is membrane tr...Continue Reading
References
Mar 1, 1977·Clinical and Experimental Pharmacology & Physiology·R Dunstan, D M Jackson
Jul 1, 1977·British Journal of Orthodontics·D H Lewis
May 24, 1979·The New England Journal of Medicine·R P Gale
Oct 1, 1979·Cancer·S A RudnickS McIntosh
Jun 1, 1992·British Journal of Haematology·G SchillerR Champlin
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R ChamplinW Ho
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J SchillerJ L Gajewski
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S N WolffG P Herzig
Feb 1, 1987·The Journal of Clinical Investigation·J C WhiteR L Capizzi
Feb 1, 1985·The Journal of Clinical Investigation·J S WileyL R Finch
Aug 1, 1983·European Journal of Cancer & Clinical Oncology·J S WileyW H Sawyer
Feb 1, 1982·The Journal of Clinical Investigation·J S WileyA R Paterson
Oct 6, 1994·The New England Journal of Medicine·R J MayerE Frei
Dec 1, 1993·Leukemia & Lymphoma·A T TreweekeR E Clark
Jan 1, 1980·International Review of Cytology·R M Wohlhueter, P G Plagemann
Citations
Oct 7, 2008·International Journal of Hematology·L H LindnerE Schleyer
Nov 8, 2012·International Journal of Hematology·Brian McLaughlinMichael Boyiadzis
Jul 20, 2001·Journal of Neurochemistry·H M GellerL Grandison
Feb 8, 2011·Journal of Biomaterials Science. Polymer Edition·Sumit MehrotraChristina Chan
Nov 6, 2009·PloS One·Mona MeyerAndreas Neubauer
Jun 19, 2004·Neurotoxicology and Teratology·Hirofumi YamauchiKunio Doi
Jun 24, 2004·Bioorganic & Medicinal Chemistry·Pier Giovanni BaraldiRomeo Romagnoli
Jul 16, 2015·Journal of Clinical Pharmacy and Therapeutics·H HeH H Zhou
Dec 2, 2011·The Journal of Toxicological Sciences·Kunio Doi
Feb 15, 2011·Leukemia Research·Dhaval R MehtaMichael Boyiadzis
Apr 8, 2015·PloS One·Costa BachasJacqueline Cloos
Nov 22, 2016·Expert Review of Hematology·Tapan M Kadia, Varsha Gandhi
Jan 6, 2007·Leukemia·J EsteveUNKNOWN Spanish Cooperative Group PETHEMA
Feb 1, 2010·Indian Journal of Medical Sciences·Thomas S KuruvillaZevita Furtado
Jun 29, 2014·Molecular Cancer·Magdalena KlanovaPavel Klener